Singapore Fling: AbbVie says a plant in Asia is just what it needs

Abbvie, which spun off from Abbott Laboratories since early last year, has picked Singapore for the location of a new manufacturing plant to handle ingredients for small-molecule and biologic drugs for oncology and immunology drug candidates. According to Abbvie, this move could help alleviate the problem of decrease in revenue when Humira, its best-selling drug, goes off patent in 2016, …

Guest post: Rising generics use triggers increased worldwide regulation

  This article was originally posted on GaBI Online. The increasing use of lower cost generics is prompting regulators across the globe to introduce stricter regulations focusing on the quality of these products. Just a few of the countries that have updated regulations governing generics include emerging markets such as Brazil, Mexico, Russia and South Africa. This leads to delays …

Teva’s New CEO Moves Quickly on Dealmaking

Recently, pharmaceutical company Teva has been facing numerous challenges. These include expiring patents for their top drugs, strong labour opposition to plans for restructuring, conflict between the Board of Directors and Management which resulted in the CEO’s departure, and shareholder unrest. Eyal Desheh, the CFO, has said that they have to make smart deals and partnerships like how Teva has …

Novartis petition reignites biosimilar naming debate

Last week the dispute over the naming of Biosimilars was reignited as heavyweights Novartis joined the debate. Calls by the Alliance for Safe Biological Medicines (ASBM), back in September 2012, for the FDA to give biosimilar medicines distinct scientific names started this debate. Citing possible differences in effects between bisimilar drugs, and the general belief amongst physicians and specialists that …

Download: eBook – ‘Top 10 game changers in the generics industry’

  We think the generic industry is going to look a lot different in 10 years time. Changes are being seen, the industry dynamics are evolving, trends are emerging. Asa Cox, Workshop Leader, World Generic Medicines Congress Americas 2013, Generic Pharma 2.0 has kindly put together this eBook to detail what he believes are the Top 10 potential industry game …

Download free stem cells glossary

Are you new to the stem cells industry? Do you work as a supplier to or investor in stem cells? If you're finding it difficult to keep up with the complex jargon used in the industry, you might be interested in our free stem cells glossary. The sample below will give you an idea of what's included. And if you …

Increase in generic drug use stabilises US health spend growth rate

Generic drug use in the US jumped up 8% in 2012, keeping the growth rate of health care spending stable for the third straight year. This is according to a new report from the Health Care Cost Institute, which examined claims made by Americans aged 65 and under with insurance covered by their employer. While 2011 showed a health spending …

Eli Lilly’s “unusual ammo” to fend off generic competition

Eli Lilly, who are facing rather a large patent cliff, is employing what Reuters call "unusual ammo" to fend off generic competition. Lilly is currently embroiled in a patent battle with generic drug manufacturer Teva Pharmaceutical Industries, centred around Lilly's lung cancer drug Alimta. Last summer, the US Court of Appeals upheld the validity of the patent on Alimta's chemical …